155 related articles for article (PubMed ID: 34240006)
1. Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.
Berthold F; Spix C; Erttmann R; Hero B; Michaelis J; Treuner J; Ernst A; Schilling FH
JNCI Cancer Spectr; 2021 Jul; 5(4):. PubMed ID: 34240006
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
3. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma screening at one year of age.
Schilling FH; Spix C; Berthold F; Erttmann R; Fehse N; Hero B; Klein G; Sander J; Schwarz K; Treuner J; Zorn U; Michaelis J
N Engl J Med; 2002 Apr; 346(14):1047-53. PubMed ID: 11932471
[TBL] [Abstract][Full Text] [Related]
5. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
[TBL] [Abstract][Full Text] [Related]
6. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
7. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma screening in Japan: population-based cohort study and future aspects of screening.
Hiyama E
Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):88-4. PubMed ID: 19904462
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
11. Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany.
Schilling FH; Spix C; Berthold F; Erttmann R; Sander J; Treuner J; Michaelis J
Cancer Lett; 2003 Jul; 197(1-2):19-28. PubMed ID: 12880955
[TBL] [Abstract][Full Text] [Related]
12. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B; Brodeur GM
Eur J Cancer; 1997 Oct; 33(12):2106-12. PubMed ID: 9516863
[TBL] [Abstract][Full Text] [Related]
13. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan.
Yamamoto K; Ohta S; Ito E; Hayashi Y; Asami T; Mabuchi O; Higashigawa M; Tanimura M
J Clin Oncol; 2002 Mar; 20(5):1209-14. PubMed ID: 11870162
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors.
Kerbl R; Urban CE; Ambros IM; Dornbusch HJ; Schwinger W; Lackner H; Ladenstein R; Strenger V; Gadner H; Ambros PF
J Clin Oncol; 2003 Nov; 21(22):4228-34. PubMed ID: 14615452
[TBL] [Abstract][Full Text] [Related]
15. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
16. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan.
Ajiki W; Tsukuma H; Oshima A; Kawa K
Cancer Causes Control; 1998 Dec; 9(6):631-6. PubMed ID: 10189049
[TBL] [Abstract][Full Text] [Related]
17. Screening of infants and mortality due to neuroblastoma.
Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B
N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470
[TBL] [Abstract][Full Text] [Related]
18. Screening for neuroblastoma: a 9-year birth cohort-based study in Niigata, Japan.
Asami T; Otabe N; Wakabayashi M; Kakihara T; Uchiyama M; Asami K
Acta Paediatr; 1995 Oct; 84(10):1173-6. PubMed ID: 8563231
[TBL] [Abstract][Full Text] [Related]
19. Mass screening for neuroblastoma and mortality in birth cohorts.
Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
[TBL] [Abstract][Full Text] [Related]
20. Is neuroblastoma screening evaluation needed and feasible?
Estève J; Parker L; Roy P; Herrmann F; Duffy S; Frappaz D; Lasset C; Hill C; Sancho-Garnier H; Michaelis J
Br J Cancer; 1995 Jun; 71(6):1125-31. PubMed ID: 7779698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
